Description
Decitabine is a nucleoside metabolic inhibitor indicated in order to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
Decitabine is a nucleoside metabolic inhibitor indicated in order to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
The recommended dose should be administered as an injection into the vein under the supervision of a healthcare practitioner. Your healthcare practitioner will determine what dose is appropriate and how often you need to receive it.
Most common adverse reactions include cough, fatigue, neutropenia, hyperglycemia, thrombocytopenia, nausea, anemia, pyrexia, petechiae, constipation, and diarrhea.
Is Decitabine an FDA-approved drug?
The FDA approved the drug Decitabine in 2006.
What are the alternate brands of Decitabine Injection?
How does Decitabine work?
As a hypomethylating agent, decitabine works in order to switch off a protein named DNA methyltransferase. This switches on the genes that block the cancerous cells from growing as well as dividing.
From which class of drug Decitabine belongs?
Decitabine belongs to a class of drugs known as DNA demethylating agents.
What are the ingredients of the medicine Decitabine?
The active ingredient in the medicine is Decitabine, and the inactive ingredients are monobasic potassium phosphate (potassium dihydrogen phosphate) and sodium hydroxide.
What are commonly reported side effects of decitabine?
Nausea, fever, vomiting, diarrhea, headache, and lung infection.